AIM Immunotech Inc. Form 8-K Summary
Business Context and Reporting Period
AIM Immunotech Inc. (AIM) filed a Current Report on Form 8-K dated November 18, 2025. The filing reports the entry into a material definitive agreement and the creation of a direct financial obligation through a private placement transaction.
Key Financial Metrics and Transaction Details
The Company consummated a private placement of an unsecured Promissory Note with Streeterville Capital, LLC. Key terms include:
- Principal Amount: $3,301,250
- Net Proceeds: $2,500,000 (after deducting a $781,250 original issuance discount and $20,000 in transaction costs)
- Interest Rate: 10% per annum, compounded daily
- Maturity Date: 24 months from issuance (November 18, 2027)
- Repayment Terms: Mandatory prepayments required upon future fundraising (lesser of 12.50% of funds raised or outstanding balance); optional monthly redemptions of up to $250,000 available to the investor starting six months post-issuance.
Material Changes and Obligations
This filing represents a new material debt obligation not present in prior periods. The Note includes customary events of default, including non-payment, bankruptcy, and cross-defaults. Upon an Event of Default, the interest rate increases to the lesser of 22% or the maximum rate permitted by law.
Guidance, Risks, and Contingencies
The filing does not provide updated financial guidance or management commentary regarding future operations. The primary risk disclosed is the liquidity constraint imposed by the mandatory prepayment clause, which requires the Company to divert 12.50% of any future fundraising proceeds to repay this Note. Additionally, the Company faces a potential cash outflow of up to $250,000 per month starting six months after issuance if the investor exercises redemption rights.
Investor Verification Checklist
- Verify the Company's current cash position to assess ability to meet potential monthly redemption requests.
- Review the impact of the 12.50% mandatory prepayment clause on the economics of any future capital raises.
- Confirm the total outstanding debt load including this new $3.3M obligation.
- Examine the full text of the Note Purchase Agreement (Exhibit 10.1) for additional covenants not summarized in the 8-K.